ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $4,266,350.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 55,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the sale, the chief executive officer owned 349,889 shares in the company, valued at $27,140,889.73. This represents a 13.58% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ANI Pharmaceuticals Price Performance

Shares of ANIP traded up $1.38 during trading hours on Wednesday, hitting $80.88. The stock had a trading volume of 308,836 shares, compared to its average volume of 412,504. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 20.48 and a beta of 0.46. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The company’s fifty day moving average is $77.08 and its two-hundred day moving average is $80.70. ANI Pharmaceuticals, Inc. has a 52 week low of $56.71 and a 52 week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals during the first quarter valued at $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in ANI Pharmaceuticals by 0.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after purchasing an additional 423 shares during the period. Jane Street Group LLC bought a new stake in ANI Pharmaceuticals during the 1st quarter worth about $2,706,000. Finally, Norges Bank bought a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $625,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Guggenheim boosted their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.